Tag: osé
OSE Immuno: obtaining public aid – 08/01/2023 at 08:00
(CercleFinance.com) – OSE Immunotherapeutics announces that it has received innovation aid of 200,000 euros from the French Government and the Pays de la Loire Region, as part of the ‘France…
OSE Immunotherapeutics: publication on OSE-230 in ‘Frontiers in Immunology’
By Alexandra Saintpierre Published on 07/19/2023 at 6:33 p.m. (Boursier.com) — OSE Immunotherapeutics SA announces the publication,…
OSE Immunotherapeutics: new publication on the OSE-230 antibody – 07/19/2023 at 18:21
(AOF) – OSE Immunotherapeutics announces the publication of the latest results on the pro-resolving monoclonal antibody OSE-230, an innovative new approach in the resolution of severe and chronic inflammation, in…
OSE Immunotherapeutics: new publication on the OSE-230 antibody
(AOF) – OSE Immunotherapeutics announces the publication of the latest results on the pro-resolving monoclonal antibody OSE-230, an innovative new approach in the resolution of severe and chronic inflammation, in…
OSE Immuno: end of recruitment for a phase 1/2 trial – 07/11/2023 at 18:09
(CercleFinance.com) – OSE Immunotherapeutics and the Center Hospitalier Universitaire de Nantes announce the end of patient recruitment in the FIRsT study, a phase 1/2 clinical trial. This is the first…
Ose immuno: End of recruitment for a phase 1/2 trial
Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service…
OSE Immuno: end of recruitment for a phase 1/2 trial
(CercleFinance.com) – OSE Immunotherapeutics and the Center Hospitalier Universitaire de Nantes announce the end of patient recruitment in the FIRsT study, a phase 1/2 clinical trial. This is the first…
Ose immuno: Driven by a new patent for its anti-lung cancer, OSE Immuno is progressing on the stock market
(BFM Bourse) – The Nantes biotechnology company announced on Tuesday evening that it had expanded its patent portfolio internationally. OSE Immunotherapeutics has indeed obtained a new patent in the United…
Ose Immuno: received a new patent from the USPTO – 07/05/2023 at 08:13
(CercleFinance.com) – OSE Immunotherapeutics announces that the United States Patent and Trademark Office (USPTO) has granted it a new patent protecting Tedopi®, its therapeutic cancer vaccine, for the treatment of…
Ose Immuno: new US patent protecting Tedopi until 2037
(CercleFinance.com) – OSE Immunotherapeutics announces that the United States Patent and Trademark Office (USPTO) has granted it a new patent protecting Tedopi®, its therapeutic cancer vaccine, for the treatment of…
OSE Immunotherapeutics receives €1.5 million in funding from Bpifrance for the development of a companion diagnostic test associated with Tedopi®, its vaccine against non-small cell lung cancer – 06/20/2023 at 18:00
• Funding of 1.5 million euros from Bpifrance – Regional Direction of Nantes within the framework of the “R&D Innovation Loan” program. • Development of a companion diagnostic test to…
Oncology: OSE Immunotherapeutics receives 1.5 million euros from Bpifrance – 06/20/2023 at 18:07
(AOF) – OSE Immunotherapeutics announces today that it has received non-dilutive funding of 1.5 million euros from Bpifrance. The “R&D Innovation Loan” program aims to support the development of a…